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Available online 29 January 2019Objective:Glucagon-like-peptide-1 (GLP-1) receptor analogues have been shown to reduce cardiovascular events
in patients with type 2 diabetes. However, the mechanism behind is still unknown. The aim of the study was to
investigate the effect of intact GLP-1 (7–36) on coronary microcirculation in overweight adults.
Design and methods: A double-blinded randomized cross-over study was performed, with 12 overweight partici-
pants. Effects of intact GLP-1 (7-36) infusionwere comparedwith a saline infusion on separate days. ADPP-4 inhib-
itor was administered to block degradation of intact GLP-1 (7–36) to the GLP-1 metabolite (9–36). Coronary
microcirculation was assessed by Doppler coronary ﬂow velocity reserve (CFVR) before and after 2 h of infusion.
Peripheral endothelial functionwas assessedbyﬂowmediated dilation (FMD)before and after onehour of infusion.
Results: CFVR was 3.77 ± 1.25 during GLP-1 infusion and 3.85 ± 1.32 during saline infusion, endothelial function
was 16.3 ± 15.5 % during GLP-1 infusion and 7.85 ± 7.76 % during saline infusion. When adjusting for baseline
values no signiﬁcant differences in CFVR (ΔCFVR 0.38 ± 0.92 vs.ΔCFVR 0.71 ± 1.03, p= 0.43) and no difference
in peripheral endothelial function (ΔFMD 7.34 ± 11.5 % vs.ΔFMD –1.25 ± 9.23%, p= 0.14) was found.
Conclusions:We foundno effect of intactGLP-1 (7–36), protected fromDPP4mediated degradation on coronarymi-
crocirculation in overweight adults.
© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Glucagon-like peptide-1 (GLP-1), an incretin hormone produced by
intestinal L-cells in response to meal intake, acts to reduce postprandial
glucose levels [1,2]. However GLP-1 receptors have been localized in
most organs of the human body including the heart [3,4] and in addition
to its well-characterized glycaemic actions, studies in both animals and
humans have repeatedly demonstrated a beneﬁcial action of GLP-1 on
the cardiovascular system [5–7]. However, the physiological effects of
GLP-1 on the heart still raise many questions. In patients with type 2, major adverse cardiac event;
icrovascular dysfunction; FMD,
E, trans-thoracic Doppler echo-
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y. No other uses without permissiondiabetes, semaglutide, liraglutide and albiglutide (GLP-1 analogues)
have been shown to reduce the risk of cardiovascular events and
mortality in large prospective outcome trials [8–10], but themechanism
behind is still unknown.
Coronary microvascular circulation is the ability to increase
vasodilator reserve of the small coronary arteries in response to increase
oxygen demand and thus coronary microvascular dysfunction (CMD) is
deﬁned as reduced vasodilator reserve of the small coronary arteries in
response to increased oxygen demand. CMDmay precede development
of macrovascular atherosclerosis [11,12] and is associated with in-
creased cardiovascular mortality [13]. Type 2 diabetes and obesity are
associated with CMD [13,14]. A former study performed by our group
indicated that long-term treatment with liraglutide, a GLP-1 receptor
agonist, may improve CMD in patients with type 2 diabetes [15]. How-
ever, hyperglycaemia per se seems to impair coronary microvascular
function [16] and several studies have shown thatweight loss improves
CMD. Therefore, the effect of long-term treatmentwithGLP-1 analogues
on CMD may be indirect caused by weight loss and improvements in
HbA1c.
Both endothelial dependent and independent pathways may lead to
coronary microvascular dysfunction [17,18]. As CMD, endothelialthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
nhagen from ClinicalKey.com by Elsevier on October 23, 2019.
. Copyright ©2019. Elsevier Inc. All rights reserved.
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erosclerosis and is associated with obesity and type 2 diabetes [19,20].
The aim of the present study was to investigate the effect of intact
GLP-1 on coronary microvascular function and peripheral endothelial
function in obese individuals without diabetes.
2. Method
2.1. Study protocol
The studywas designed and performed in accordance to theHelsinki
Declaration of Good Clinical Practise and approved by the ethical
committee of Region Hovedstaden, Denmark, and the Danish Health
andMedicines Authority. All participants gave oral and written consent
before participation.
The study was registered at www.clinicaltrials.gov (NCT02333591).
2.2. Study population
Thirteen overweight adults were included in the study, but one
was excluded due to side-effects. Twelve overweight adults (7 male/5
female) completed, all were healthy, non-smokers with no history
of cardiovascular disease. Participants who met inclusion criteria
underwent a treadmill exercise test with two-dimensional echocardi-
ography, performed by experienced cardiologists, to exclude coronary
macrovascular disease.
2.3. Study design
A randomised, double-blinded, crossover study was conducted,
consisting of two infusion treatments: (1) 2.5 h intravenous infusion
of intact GLP-1 (7–36) in combination with oral administration of
DPP-4 inhibitor (100 mg Sitagliptin taken the night before infusion
and 100 mg Sitagliptin taken immediately before infusion) (2) 2.5 h
intravenous infusion of saline, with awashout period of at least 24 h be-
tween infusion 1 and 2. DPP-4 inhibitor is added to prevent degradation
of GLP-1 (7–36) to the GLP-1 metabolite, which would otherwise occur
rapidly by the enzyme depetidyl-peptidase-4 (DPP-4).
All participants received both treatments in a randomised order
after an over-night fast. They refrained from caffeine and food contain-
ing signiﬁcant amounts of methylxanthine (coffee, tea, chocolate, cola,
and bananas) for 24 h prior to the treatments.
Coronary ﬂow velocity reserve (CFVR) was measured by trans-
thoracic Doppler ﬂow echocardiography (TTDE) of the left anterior de-
scending artery (LAD) before every infusion, and after 2 h of infusion.
Peripheral endothelial function was measured by ﬂow mediated dila-
tion (FMD) before every infusion and after 1 h of each infusion. Heart
rate and blood pressure were measured using an electric sphygmoma-
nometer according to standardized procedures every 30min during in-
fusion. Venous blood samples were drawn for 7-point measurements
for every infusion period; the ﬁrst two were drawn at baseline with
15 minute interval, and thereafter every half hour during the infusion.
The last sample was drawn just before infusion was discontinued.
Blood samples were analysed for glucose, insulin, C-peptide, glucagon,
total GLP-1 (i.e., GLP-1 (7–36) + GLP-1 (9–36)) and GLP-1 (7–36). A
DPP-4 inhibitor (valine pyrrolidide; 0.01 mmol/L) was added to chilled
EDTA tubes for GLP-1 (7–36) measurement to prevent post-sampling
degradation of GLP-1.
2.4. Peptide
Puriﬁed GLP-1 (7–36) ready for human use was purchased as a
Clinalfa product from Bachem AG (Bubendorf, Switzerland), and was
stored frozen at −20° until use. On the examination day, GLP-1 was
diluted in saline and human serum albumin was added to the solutionDownloaded for Anonymous User (n/a) at BS - University of Cope
For personal use only. No other uses without permissionto a ﬁnal albumin concentration of 2% to avoid binding of the compound
to the infusion material.
A gradually declining bolus infusionwas given during the ﬁrst 10min
(5.91 pmol/kg/min until time2min, 2.53 until time4min, 2.34 until time
6 min, 2.2 until time 8 min, 2.02 until time 10 min). From time 10 min,
the infusion rate was 1.5 pmol/kg/min until the end of examination, ex-
pected to result in a “therapeutic”, slightly supraphysiological plasma
concentration of GLP-1 of approximately 100 pmol/l [21].
2.5. Analyses
Plasma glucose wasmeasured by the glucose oxidase method, using
a glucose analyser (Yellow Springs Instrument, YSI Inc., Yellow Springs,
OH). Serum insulin and C-peptide levels were determined using the
IMMULITE 2000 immunoassay system (Siemens Healthcare, Erlangen,
Germany). Glucagon and GLP-1 concentrations in plasma were mea-
sured after extraction of plasma with 70% ethanol. The glucagon radio-
immunoassay was directed against the C-terminus of the glucagon
molecule (antibody code no. 4305) and therefore mainly measures glu-
cagon of pancreatic origin [22,23]. Plasma concentrations of GLP-1 were
measured [24] against standards of synthetic GLP-1 (7–36) amide using
antiserum code no. 89390, which is speciﬁc for the amidated
C-terminus of GLP-1 and therefore mainly reacts with GLP-1 of intesti-
nal origin. The assay reacts equally with intact GLP-1 and with GLP-1
(9–36) amide, the primary metabolite. For both assays, sensitivity was
below 1 pmol/l, intraassay coefﬁcient of variation below 6% at
20 pmol/l, and recovery of standard, added to plasma before extraction,
about 100% when corrected for losses inherent in the plasma extraction
procedure.
Intact GLP-1 (7–36) wasmeasured using a 2-site sandwich assay in-
volving 2 monoclonal antibodies; C-terminal GLP-1F5 and N-terminal
Mab26.1 [25]. Standards are GLP-1 (7–36) amide prepared in human
plasma depleted of endogenous intact GLP-1 immunoreactivity. Detec-
tion limit b0.5 pmol/l. Intra- and inter-assay coefﬁcient of variations
are 2 and 5%, respectively. Quality control (QC) samples (“low” and
“high”) are included in each assay, alongside the samples. HOMA-IR
was obtained using the HOMA2 calculator (available at www.dtu.ox.
ac.uk/homacalculator/), using fasting concentrations of glucose and in-
sulin from the ﬁrst day of examination.
2.6. Echocardiography
Echocardiographic examinations with measurement of coronary
ﬂow velocities were performed using a GE Healthcare Vivid E9 cardio-
vascular ultrasound system (GE Healthcare, Horten, Norway) with a
2.7–8 MHz transducer (GE Vivid 6S probe) for TTDE. Two experienced
echocardiographers performed all examinations in the same setting.
All four examinations of each participant were performed by the same
echocardiographer. The echocardiographer was blinded to the infusion
product.
As previously described [26], coronaryﬂowvelocitiesweremeasured
in the LAD by pulsed-wave Doppler as a laminar ﬂow towards the trans-
ducer during rest and high-dose adenosine infusion over 6 min (0.14
mg/kg/min). CFVR was calculated as the ratio between peak velocities
during stress and during rest. Every examination was analysed indepen-
dently by two experienced echocardiographers blinded to subject data.
The second reading was used except in case of discrepancies (estimates
differing by N0.2) in which case the examination was re-evaluated by
the two analysers and an agreement was reached.
In the absence ofmajor coronary artery stenosis, CFVRmeasures cor-
onary microcirculation. The regarded reference standard for measuring
coronary microcirculation is by positron emission tomography (PET).
However, previous validation studies have shown high inter- and
intra-observer reproducibility of CFVR measured by TTDE [27–29].
Rate pressure product (RPP), ameasurement ofmyocardial demand,
was calculated as heart rate multiplied by systolic blood pressure. CFVRnhagen from ClinicalKey.com by Elsevier on October 23, 2019.
. Copyright ©2019. Elsevier Inc. All rights reserved.
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locities at rest by the rate pressure product and multiplying with
10,000 [27].2.7. Peripheral vascular function by ﬂow-mediated dilation
Endothelial function was measured by FMD according to guidelines
[30]. Examinations were done before and after 60 min of infusion. To
minimize potentially negative effects of environmental and physiologi-
cal inﬂuences, participants rested for at least 20 min in a room with
monitored temperature (22–25 °C), prior to examination. The ultra-
sound transducer was placed parallel to the brachial artery 3–5 cm
proximally of the antecubital fossa.When high quality image of the bra-
chial artery was acquired, baseline arterial diameter was determined
continuously for 1 min, followed by rapid cuff inﬂation to occlusion at
300 mm Hg for 5 min. Flow and diameter of the brachial artery were
measured continuously from 30 s before rapid cuff deﬂation and during
the following 2.5min. After 10minute resting period, the endothelium-
independent response (nitroglycerine-mediated dilation (NMD)) was
performed. Ultrasound images were continuously recorded and ob-
tained using the sameGEHealthcare Vivid E9 cardiovascular ultrasound
system with a 10 MHz linear array transducer (GE Vivid 9L probe) in
duplex mode.
Image analyses were performed ofﬂine using state-of-the-art auto-
matic edge-detection software (Vascular Tools 6, MIA, LLC, IA, USA).
Peak dilation within 2.5 min from cuff deﬂation, FMD, was determined
as themaximum5-second averaged diameter in percent of the baseline
diameter.
The unscaled FMD, the NMD response, the resting and peak arterial
diameter as well as time to peak, were reported.2.8. Calculations and statistical analysis
Sample size was estimated prior to study commencement: 10
subjects should complete the study based on the ability to detect a
0.3 change in CFVR with a power of 80% and a two-sided signiﬁcance
level of 0.05. A change of 0.3 in CFVR was considered of clinical
importance.
CFVR (with and without correction for RPP), FMD, blood pressure,
pulse and blood sample levels from the two infusion days were
compared. Results are shown as mean or as delta values with standard
deviation on each examination day. Linear mixed modelling was used
for the analysis of repeated measures and followed by the post hoc
Bonferroni's test. The effect of the intervention on CFVR and FMD
was analysed using linear mixed modelling with subject-speciﬁc
and subject-within-visit random effects. The model included a time-
treatment-visit-interaction. A potential carry-over effect was adjusted
for. Differences resulting in values of p b 0.05were considered signiﬁcant.
The graphical illustrations were performed using GraphPad Prism
(version 7.02; GraphPad software) and statistical analyses were





p T = 120 p Baseline Du
in
Heart rate (beats/min) 53 ± 10 56 ± 10 0.02 56 ± 10 0.08 57 ± 10 6
sBP (mm Hg) 129 ± 14 129 ± 13 0.35 131 ± 14 0.58 125 ± 11 13
dBT (mm Hg) 74 ± 10 74 ± 10 0.37 74 ± 8 0.86 75 ± 8 7
Data are means ± SD. Vital sign data in obese adults at baseline, on average throughout infusio
blood pressure; dBP, diastolic blood pressure. Δ is change between baseline and timepoint 120
⁎ Is comparison of change from baseline to time point 120 min, between saline and GLP-1 in
Downloaded for Anonymous User (n/a) at BS - University of Copenha
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Twelve subjects completed the study, mean age was 54 ± 9.7 years
and mean BMI was 30.9 ± 2.9 kg/m2. All had central obesity, measured
by waist circumference, of 104± 9 cm. HOMA2 IR was 0.81 ± 0.50 and
HbA1c was 36.8 ± 2.3 mmol/mol (Supplemental Table I).
3.1. Glucose
A time × intervention interaction was found in the repeated mea-
sure of plasma glucose (PG) (p ≤ 0.0001) (Supplemental Fig. I). Baseline
PGdid not differ between infusion days, but PG concentration decreased
during infusionwith GLP-1. Themean difference in PG between the two
infusions measured just before the CFVR examination was 0.5 mmol/l
(4.9 vs 5.4 mmol/l, p = 0.02). However, PG stayed within normal
range throughout infusions with a nadir of 4.0 mmol/l during GLP-1
infusion.
3.2. Vital signs
Throughout the GLP-1 infusion heart rate increased from 57 ±
10 beats/min to 64 ± 11 beats/min (p= 0.0004) (Table 1). Just before
CFVRmeasurement heart rate was increased by 6 beats/min (p=0.009)
compared to baseline, and by 7 beats/min compared to saline infusion
(p = 0.0002) (Supplemental Fig. IIA). We found a signiﬁcant increase
in average systolic blood pressuremeasured throughout theGLP-1 infu-
sion compared to baseline (from 125 ± 11 to 138 ± 13 mm Hg, p =
0.007) (Supplemental Fig. IIB). However, no signiﬁcant difference was
found when comparing delta values of systolic blood pressure between
the two infusion days (Table 1).
No overall difference was found for diastolic blood pressure.
3.3. GLP-1
Total plasma GLP-1 (Fig. 1A) and plasma GLP-1 (7–36) (Fig. 1B)
increased signiﬁcantly within the ﬁrst 30 min of infusion compared to
saline and were maintained at supraphysiological levels throughout
GLP-1 infusion. The mean level of GLP-1 (7–36) just before CFVR mea-
surement was 117.3 pmol/l versus 0.4 pmol on saline (p ≤ 0.0001).
3.4. Insulin, C-peptide and glucagon
Insulin (Fig. 1C) and C-peptide (Fig. 1D) showed similar curves, with
GLP-1 infusion causing a rise in both, peaking at 30 min and thereafter
returning to basal levels. Before the CFVR measurement, there were
no difference between GLP-1 and saline infusion.
No signiﬁcant changes in plasma glucagon were seen between
GLP-1 and saline infusion.
3.5. Coronary ﬂow velocity reserve
Median baseline CFVR was 3.26 ± 0.81 and none of the participants
had impaired coronary microvascular function (deﬁned as CFVR b 2).Intervention effect
ring
fusion
p T = 120 p Saline Δ GLP-1 Δ Estimate p⁎
4 ± 11 0.0004 63 ± 11 0.009 2.6 ± 4.7 6.7 ± 7.4 4.08 0.15
6 ± 12 0.007 138 ± 13 0.02 1.9 ± 11.8 13.2 ± 16.5 11.3 0.07
8 ± 9 0.18 75 ± 10 0.98 −0.5 ± 9.9 −0.2 ± 10.6 0.33 0.94
ns and after 120 min of infusion of saline or glucagon-like peptide-1 (7–36). sBP, systolic
min.
fusion.
gen from ClinicalKey.com by Elsevier on October 23, 2019.
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Fig. 1. Concentrations (means ± SEM) of total GLP-1 (A), GLP-1 (7–36) (B), insulin (C) and C-peptide (D). CFVR: coronary ﬂow velocity reserve.
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(CFVR was 3.77 ± 1.25 during GLP-1 infusion vs. 3.85 ± 1.32 during sa-
line infusion). When comparing delta values, there were neither any sig-
niﬁcant differences between GLP-1 and saline infusion (ΔCVFR 0.38 ±
1.03 vs. Δ0.71 ± 0.0.92, p = 0.43). Coronary ﬂow velocities corrected
for rate pressure product (e.g. heart rate and systolic blood pressure)
did not alter the p value (Table 2).
3.6. Peripheral vascular function
Seven participants had valid FMD measurements from both exami-
nation days. We found no effect of intact GLP-1 infusion on endothelial
dependentmicrovascular function assessed by FMD compared to saline
infusion (ΔFMD 7.34 ± 11.5 vs. ΔFMD −1.25 ± 0.9.23, p = 0.14)
(Table 3).
3.7. Adverse effects
Five of 13 included participants experienced a transientmild nausea
during infusion of GLP-1, three had more severe nausea and wereTable 2
Coronary ﬂow velocities.
Saline GLP-1
Baseline T = 120 Δ p Baselin
CFVR 3.13 ± 0.85 3.85 ± 1.32 0.71 ± 1.03 0.02 3.39 ±
CFV at rest 0.24 ± 0.06 0.19 ± 0.06 −0.05 ± 0.03 0.06 0.21 ±
CFV at hyperaemia 0.72 ± 0.16 0.69 ± 0.19 −0.04 ± 0.14 0.39 0.69 ±
CFVR RPP corrected 2.15 ± 0.77 2.80 ± 1.20 0.65 ± 0.98 0.04 2.35 ±
Data aremeans± SD. Coronaryﬂowvelocities in obese adults at baseline and after 120min infu
coronary ﬂow velocity; RPP, rate pressure product. Δ is change between baseline and timepoin
⁎ Is comparison of change from baseline to time point 120 min, between saline and GLP-1 in
Downloaded for Anonymous User (n/a) at BS - University of Cope
For personal use only. No other uses without permissionvomiting during GLP-1 infusion, one of the three were excluded for
this reason. Vomiting is a well-known side effect to acute administra-
tion of GLP-1. No side effects were observed during saline infusion.4. Discussion
We found no effect of infusion of intact GLP-1 on coronary ﬂow
velocity reserve and no effect on peripheral endothelial function and
thus no indication of a direct effect of intact GLP-1 on coronary micro-
vascular function in overweight adults without diabetes.
Several studies have indicated beneﬁcial effects of GLP-1 on the car-
diovascular system [8–10]. Treatment with the GLP-1 analogue,
Liraglutide, signiﬁcantly reduced the risk of MACE and mortality from
cardiovascular disease in patients with type 2 diabetes [8]. The once
weekly GLP-1 analogues semaglutide and albiglutide also reduced the
risk of MACE in patients with type 2 diabetes though no signiﬁcant re-
duction in death from cardiovascular disease were observed [9,10].
The mechanism of risk reduction by GLP-1 treatment is unknown
though antiatherogenic effects may be an explanation [31].Intervention effect
e T = 120 Δ p Estimate CI p⁎
0.79 3.77 ± 1.25 0.38 ± 0.92 0.15 −0.33 −1.16;0.50 0.43
0.05 0.23 ± 0.08 0.02 ± 0.09 0.50
0.13 0.79 ± 0.13 0.10 ± 0.17 0.0003
0.54 3.27 ± 1.28 0.92 ± 1.02 0.01 0.27 −0.57;1.11 0.53
sion of saline or glucagon-like peptide-1 (7–36). CFVR, coronaryﬂowvelocity reserve; CFV,
t 120 min.
fusion.
nhagen from ClinicalKey.com by Elsevier on October 23, 2019.
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Table 3
Flow mediated dilation.
Saline GLP-1 Intervention effect
Baseline T = 60 Δ p Baseline T = 60 Δ p Estimate CI p⁎
FMD (%) 9.10 ± 5.08 7.85 ± 7.76 −1.25 ± 9.23 0.73 8.94 ± 7.31 16.3 ± 15.5 7.34 ± 11.5 0.14 8.97 −2.99;20.9 0.14
Baseline diameter (mm) 3.57 ± 0.65 3.70 ± 0.53 0.13 ± 0.19 0.12 3.61 ± 0.61 3.64 ± 0.69 0.026 ± 0.15 0.66
Peak diameter (mm) 3.90 ± 0.82 3.99 ± 0.65 0.082 ± 0.49 0.68 3.92 ± 0.58 4.17 ± 0.59 0.26 ± 0.31 0.07
Time to peak (s) 43 ± 20 49 ± 46 6 ± 63 0.27 98 ± 54 76 ± 47 −21 ± 76 0.49
NMD (%) 24.4 ± 7.5 27.9 ± 6.9 3.44 ± 4.0 0.06 23.2 ± 6.9 35.5 ± 14.1 12.3 ± 16.1 0.09 8.12 −5.00;21.2 0.23
Data are means± SD. Flowmediated dilation in obese adults at baseline and after 60min infusion of saline or glucagon-like peptide-1 (7–36). FMD, ﬂowmediated dilation; NMD, nitro-
glycerine mediated dilation. Δ is change during placebo or active infusion.
⁎ Is comparison of change from baseline to time point 60 min, between saline and GLP-1 infusion.
143M. Nilsson et al. / IJC Heart & Vasculature 22 (2019) 139–144Coronary microvascular dysfunction and peripheral endothelial
function is associated with obesity, diabetes, hypertension and
dyslipidaemia. CMD may precede macrovascular atherosclerosis
[11,12] and is an independent predictor of cardiovascular disease
[13,14]. Obesity and type 2 diabetes are characterized by a chronic
low-grade inﬂammation associated with increased oxidative stress
and high plasma levels of various atherogenic lipids leading to increased
risk of endothelial dysfunction and cardiovascular disease [32]. Studies
have indicated a direct and indirect anti-inﬂammatory effect of GLP-1
[33,34].
However, only few studies have examined the effect of GLP-1 on cor-
onarymicrovascular function. In obese patients with type 2 diabetes the
GLP-1 receptor agonist exenatide, administered for 12weeks, improved
coronary microvascular function with concomitant improvement
in HbA1c and weight loss [35]. In a randomised cross-over study
10 weeks treatment with the GLP-1 analogue liraglutide non-
signiﬁcantly improved coronary microvascular function concomitantly
with signiﬁcant weight loss and improvement in HbA1c [15]. Extensive
weight loss following gastric bypass [36] as well as a more moderate
weight loss of 10% obtained by lifestyle intervention in overweight
women [37] improved coronary microvascular function. Furthermore,
hyperglycaemia per se seems to impair coronary microvascular
function. Thus, the effect of long-term treatmentwith GLP-1 on coronary
microcirculationmay be indirect due toweight loss and improvement in
HbA1c.
To our knowledge only one other study has examined the acute ef-
fect of GLP-1 on coronary microcirculation. In contrast to our ﬁndings,
Subaran el al. found signiﬁcant increase in myocardial microvascular
blood ﬂow, assessed by microbubble void imaging, after acute infusion
of intact GLP-1 [38]. Their patient population was young healthy indi-
viduals (18–35 years of age) with normal body weight (BMI 21.8 ±
0.4 kg/m2). In contrast we ﬁnd no increase in coronarymicrocirculation
in obese older subject after acute infusion of intact GLP-1. Thus, there
may be differences in the physiological action of intact GLP-1 in young
healthy individuals compared to older overweight people. Differences
in GLP-1 secretion and action between healthy subjects, obese subjects
and patients with type 2 diabetes have formerly been documented
[39,40]. A newly published study with prolonged treatment with the
GLP-1 analogue liraglutide in overweight patients with heart failure
showed no improvement in CFVR [41] supporting our ﬁndings of no
direct effect of GLP-1 on the microcirculation in obese subjects.
By infusion of intact GLP-1, a high concentration of metabolite will
be present in the circulation [42] as intact GLP-1 is metabolized by the
ubiquitous enzyme DPP-4 [2]. In contrast to the study by Subaran
et al., we administered anoral DPP-4 inhibitor prior to our examinations
to rule out an effect of the metabolite, focusing only on the effect of
intact GLP-1, which exert its effect through the GLP-1 receptor. Thus,
discrepancies between our results and the study by Subaran et al. [38]
may be explained by the level of GLP-1 metabolite and intact GLP-1 or
inﬂuence of other hormone and metabolite changes caused by the
DPP-4 inhibition [7].
We found that intact GLP-1 infusion increased heart rate by 7 beats
per minutes and systolic blood pressure by 13 mm Hg, though bloodDownloaded for Anonymous User (n/a) at BS - University of Copenha
For personal use only. No other uses without permission. Cpressure was only borderline signiﬁcantly increased when compared
to saline infusion. GLP-1 analogues are known to increase heart rate
and furthermore, GLP-1 receptors have been identiﬁed in the sinoatrial
node [43] thus increased heart rate may be direct receptor mediated.
We found no effect of intact GLP-1 infusion on peripheral endothe-
lial function in overweight adults, and it is unclear whether the GLP-1
receptor is expressed in endothelial cells. Previous studies have exam-
ined the effect of GLP-1 on endothelial function, however the results
have been contradicting [6,44–47]. Devin et al. demonstrated that infu-
sion of GLP-1 into the brachial artery had no effect on forearm blood
ﬂow [44]. Like our study, the investigators added a DPP-4 inhibitor,
thereby avoiding potential inﬂuence of degrading metabolites. Further-
more, other studies found no effect on endothelial function during long-
term treatmentwith liraglutide in patients with type 2 diabetes [45,46].
In the present study, obese participants with normal glucose toler-
ancewere studied, to avoid the confounding effect of changes in plasma
glucose during the experimental days. Another strength of our study is
that the plasma levels of GLP-1 obtained during infusion correspond
to the plasma levels reported during treatmentwith GLP-1 receptor an-
alogues [48]. A limitation of our study is our small sample size. However,
we performed a power calculation prior to the study, based on a former
study by our group in which we needed 10 participants to detect a
change of 0.3 which is considered of clinical importance. Though, in
our study we had a considerable inter-measurement variability we see
no tendency of improved CFVR and thus we have no reason to believe
in a type 2 error.
5. Conclusion
We found no effect of DPP-4-protected intact GLP-1 on coronary
microcirculation nor on peripheral vascular function in obese glucose
tolerant adults.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ijcha.2019.01.004.
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